首页> 外文期刊>Biofabrication >In vitro and in vivo angiogenic capacity of BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures
【24h】

In vitro and in vivo angiogenic capacity of BM-MSCs/HUVECs and AT-MSCs/HUVECs cocultures

机译:BM-MSCs / HUVECs和AT-MSCs / HUVECs共培养的体外和体内血管生成能力

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study was to comparatively evaluate the angiogenic capacity of cocultures using either human bone marrow- or human adipose tissue-derived mesenchymal stem cells(MSCs) (BM- or AT-MSCs) with human umbilical vein endothelial cells (HUVECs) both in vitro and in vivo at early time points (i.e. days 3 and 7). In vitro, cells were either monocultured (i.e. BM-MSCs, AT-MSCs or HUVECs) or cocultured (i.e. BM-MSCs/HUVECs and AT-MSCs/HUVECs) on Thermanox R-(2-dimensional, 2D) or in collagen gels (3-dimensional, 3D). For the in vivo experiment, cells (cocultures) were embedded in collagen gels and implanted subcutaneously in nude mice. For both in vitro and in vivo experiments, samples were collected on days 3 and 7 and histologically processed for hematoxylin-eosin and platelet endothelial cell adhesion molecule (PECAM-1; CD31) staining. For in vivo samples, quantitative parameters for evaluating angiogenesis included CD31-positive staining percentage, total vessel-like structure (VLS) area percentage, VLS density, and average VLS area (i.e. the size of per VLS). In vitro results showed the formation of VLS in both cocultures, while none of the monocultures showed VLS formation, irrespective of 2D or 3D culture condition. Although VLS formation occurred after in vivo implantation, no significant difference in angiogenic capacity was observed between the two cocultures, either on day 3 or on day 7. Further, VLS density decreased and anastomosis of the new human vessels with the murine host vasculature occurred over time. In conclusion, this study demonstrated that AT-MSCs/HUVECs and BM-MSCs/HUVECs have equal angiogenic capacity both in vitro and in vivo, and that vessels from donor origin can anastomose with the host vasculature within seven days of implantation.
机译:这项研究的目的是比较评估人类骨髓或人类脂肪组织间充质干细胞(MSCs)(BM-或AT-MSCs)与人脐静脉内皮细胞(HUVECs)共同培养的血管生成能力在早期时间点(即第3天和第7天)进行体外和体内试验。在体外,将细胞在Thermanox R-(二维,2D)或胶原凝胶中进行单培养(即BM-MSC,AT-MSC或HUVEC)或共培养(即BM-MSC / HUVEC和AT-MSC / HUVEC)。 (3维,3D)。对于体内实验,将细胞(共培养物)包埋在胶原蛋白凝胶中并皮下植入裸鼠中。对于体外和体内实验,均在第3天和第7天收集样品,并进行组织学处理,以进行苏木精-曙红和血小板内皮细胞粘附分子(PECAM-1; CD31)染色。对于体内样品,评估血管生成的定量参数包括CD31阳性染色百分比,总血管样结构(VLS)面积百分比,VLS密度和平均VLS面积(即每个VLS的大小)。体外结果显示两种共培养物中均形成VLS,而无论2D或3D培养条件如何,单培养物中均未显示VLS形成。尽管在体内植入后发生了VLS的形成,但在第3天或第7天,两种共培养物之间未观察到血管生成能力的显着差异。此外,VLS密度降低,并且新的人类血管与鼠宿主血管系统发生了吻合。时间。总之,这项研究表明,AT-MSCs / HUVECs和BM-MSCs / HUVECs在体内和体外具有相等的血管生成能力,并且来自供体的血管可以在植入后的7天内与宿主脉管吻合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号